

	Placebo	Pirfenidone (2403 mg/day)	Pirfenidone vs. placebo
Number of Patients	N/A	N/A	555
Number of Evaluable Patients	N/A	N/A	N/A
Mean decline from Baseline to Week 52 in FVC volume	428 mL	235 mL	193 mL (P<0.0001)
Slope decline of FVC through week 52	262 mL/yr	122 mL/yr	140 mL/yr (P<0.0001)
<b>Hazard Ratio:</b> Death or disease progression (death, percent predicted FVC decrement of 10% or greater or 6MWD decrement of 50 meters or greater) (Endpoint=Secondary)	N/A	N/A	0.57  (P<0.001)
<b>Dyspnea endpoint:</b> >= 20 point worsening in UCSD SOBQ score or death at week 52 (Endpoint=Secondary)	36.10%	29.10%	N/A (P=0.1577)

	Placebo	Nintedanib	Nintedanib vs. Placebo
Number of Patients	N/A	N/A	N/A
Number of Evaluable Patients	N/A	N/A	N/A
Annual Rate of Decline in FVC at Week 52 <b>Overall Population</b> (Endpoint=Primary)	187.8 ± 14.8 mL/yr	80.8 ± 15.1 mL/yr	107 mL/yr (P<0.001)
Annual Rate of Decline in FVC at Week 52 <b>Patients w/UIP-Like Fibrotic Pattern</b> (Endpoint=Primary)	211.1 ± 20.5 mL/yr	82.9 ± 20.8 mL/yr	128.2 mL/yr (P<0.001)
Annual Rate of Decline in FVC at Week 52 <b>Patients w/Other Fibrotic Patterns</b> <b>Unadjusted P-Values</b> (Endpoint=Primary)	154.2 ± 21.2 mL/yr	79.0 ± 21.6 mL/yr	75.3 mL/yr (P<0.05)
Acute Exacerbation of Interstitial Lung Disease or Death at Week 52 <b>Overall Population</b> <b>Unadjusted P-Values</b> (Endpoint=Secondary)	9.70%	7.80%	N/A (P>0.05)
Acute Exacerbation of Interstitial Lung Disease or Death at Week 52 <b>Patients w/UIP-Like Fibrotic Pattern</b> <b>Unadjusted P-Values</b> (Endpoint=Secondary)	12.10%	8.30%	N/A (P>0.05)
Acute Exacerbation of Interstitial Lung Disease or Death Until First Database Lock <b>Overall Population</b> <b>Unadjusted P-Values</b>	17.80%	12.30%	N/A (P>0.05)
Acute Exacerbation of Interstitial Lung Disease or Death Until First Database Lock <b>Patients w/UIP-Like Fibrotic Pattern</b> <b>Unadjusted P-Values</b>	21.40%	13.60%	N/A (P<0.05)